Karyopharm Therapeutics Investor Presentation — June 2020

Document content

June 2020An Innovation -driven Pharmaceutical Company Focused on

Improving the Lives of Patients with Cancer and Other

Major Diseases2 ©2020 Karyopharm Therapeutics Inc. This presentation contains forward -looking statements within themeaning ofthe“safe harbor” provisions ofThe Private Securities Litigation Reform Actof1995 .Such forward -looking statements

include those regarding Karyopharm’s expectations andplans relating toselinexor asapotential treatment forpatients with multiple myeloma, diffuse large B-celllymphoma, other types ofcancer,

andCOVID -19;thedesign andexecution ofKaryopharm’s clinical trials tostudy selinexor ,including thedosing regimen ;thepotential anti-viral andanti-inflammatory properties ofselinexor ;XPOVIO

forthetreatment ofpatients with heavily pretreated multiple myeloma ;thetherapeutic potential ofandpotential clinical development plans andcommercialization forKaryopharm’s drug candidates,

including thetiming ofinitiation ofcertain trials, ofthereporting ofdata from such trials, ofthesubmissions toregulatory authorities andofpotential commercial launches ;thepotential availability of

accelerated approval pathways ;thepotential sizeofthemarkets formultiple myeloma drugs andmultiple myeloma drugs fortreatment ofpatients withrelapsed multiple myeloma ;thepotential sizeof

themarkets fordiffuse large B-celllymphoma (DLBCL) drugs andDLBCL drugs fortreatment ofpatients withrelapsed and/orrefractory DLBCL ;andKaryopharm’s strategic andfinancial plans and

expectations aswell asfinancial projections forKaryopharm, including 2020 financial guidance andthesufficiency ofcash tofund operatons through mid-2022 .Such statements aresubject to